Imagine a treatment for depression that requires no medication, no anesthesia, and no hospital stay — one where you sit in a chair for 20 minutes, feel a tapping sensation on your scalp, and go home to the rest of your day. A treatment with a response rate comparable to most antidepressants and a side effect profile that is, by psychiatric medication standards, remarkably benign.

That treatment exists. It's called Transcranial Magnetic Stimulation, and for patients in Pocatello and Southeast Idaho who have tried antidepressants without adequate relief, it represents a genuinely meaningful option that is still widely underutilized in this region.

This guide covers what TMS is, how it works, what the evidence says, who is and isn't a candidate, and what the practical experience of TMS treatment looks like.

Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique that uses rapidly alternating magnetic fields to induce small electrical currents in specific, targeted regions of the cerebral cortex — without surgery, without general anesthesia, and without the systemic effects of oral medication.

The magnetic field generated by a TMS device is similar in strength to an MRI machine's field, but highly focused and delivered in brief, repeated pulses. When directed at the left dorsolateral prefrontal cortex (DLPFC) — the primary target for depression treatment — these pulses modulate neuronal activity in a region that is consistently found to be hypoactive in major depressive disorder.

TMS was FDA-cleared for major depressive disorder in 2008. Its FDA indication was expanded to include TRD as a distinct indication, and it has since received additional clearances for OCD, smoking cessation, and anxious depression.

The dorsolateral prefrontal cortex plays a central role in executive function, emotional regulation, working memory, and the top-down modulation of the amygdala's threat and fear responses. In major depression, neuroimaging studies consistently show reduced metabolic activity and decreased connectivity in this region.

A simple way to think about it: in depression, the brain's "regulator" — the prefrontal cortex — is running too quietly to keep the rest of the mood circuitry in balance. TMS essentially nudges the regulator back online.

High-frequency TMS (10 Hz) applied to the left DLPFC is excitatory — it increases neuronal activity in an underactive region. Low-frequency TMS (1 Hz) applied to the right DLPFC is inhibitory — it quiets an overactive region. Both approaches, and sometimes combinations, are used clinically depending on the patient and the treatment protocol.

Beyond the direct local effect, TMS triggers downstream changes in connected brain regions including the limbic system and the subgenual anterior cingulate cortex — an area directly involved in the subjective experience of depression.

The original and most widely used protocol. Treatment sessions are typically 37.5 minutes, delivering 3,000 pulses at 10 Hz to the left DLPFC. A standard treatment course is 30–36 sessions over 6–9 weeks, administered Monday through Friday.

Uses a specialized H-coil that penetrates deeper and activates a broader area of cortical and subcortical tissue. Approved for depression and OCD. Session duration is similar, and it may reach regions that standard TMS coils don't.

A newer, compressed protocol that delivers the same therapeutic effect in approximately 3 minutes per session, using a burst pattern that mimics naturally occurring theta rhythms in the brain. Intermittent TBS (iTBS) applied to the left DLPFC has received FDA clearance and has been shown to be non-inferior to standard 37.5-minute protocols in large trials, dramatically improving treatment accessibility.

The most exciting recent development in TMS: an accelerated protocol delivering multiple TBS sessions per day over just 5 days (10 sessions/day × 5 days = 50 sessions total). A landmark Stanford trial found remission rates of approximately 79% in TRD patients — a dramatic improvement over standard protocols.

Clinical trials and large-scale real-world registry studies provide a clear picture of TMS efficacy:

For context: these response rates are comparable to, and in some populations superior to, adding a second antidepressant medication after a first has failed.

Patients who respond to TMS typically notice:

• Improved mood and emotional range
• Better sleep
• Increased motivation and energy
• Improved concentration
• Reduced anxiety
• The ability to experience pleasure returning

The improvement is often gradual, building over the treatment course — which is different from ketamine's rapid-onset profile.

Strong Candidates:

• Adults with major depressive disorder who have failed 1–4 antidepressant trials
• Patients who cannot tolerate antidepressant side effects
• Patients who prefer a non-pharmacological approach
• Patients with comorbid anxiety (FDA-cleared for anxious depression)
• Patients with OCD as a primary or comorbid condition (FDA-cleared)
• Elderly patients with depression where medication side effects are particularly burdensome
• Patients who have responded to TMS previously

Absolute Contraindications:

• Metallic implants in or near the head: cochlear implants, aneurysm clips, deep brain stimulators, implanted electrodes near the skull
• Active seizure disorder: uncontrolled epilepsy is a contraindication (risk of seizure induction, though rare)

Relative Contraindications (Requires Evaluation):

• Cardiac pacemakers or implantable defibrillators
• History of seizures that are currently controlled
• Active mania

Pre-treatment evaluation: A clinical assessment to confirm TRD diagnosis, review contraindications, establish baseline depression severity, and discuss goals.

Motor threshold determination: Before the first treatment, the clinician identifies your individual motor threshold — the minimum magnetic field intensity needed to produce a visible finger twitch. This calibrates the treatment dose to your individual brain anatomy.

Treatment sessions: You sit in a reclining chair, fully awake and alert. A magnetic coil is positioned against your scalp at the left DLPFC. You will feel a rhythmic tapping or clicking sensation with each pulse — sometimes described as a light woodpecker tapping. Some patients experience a mild headache during or after the first few sessions; this typically subsides.

During treatment: You can listen to music, relax, or simply sit. You remain fully conscious and communicative throughout.

After each session: You can drive and return to normal activities immediately. No recovery time is needed.

Treatment course: Standard is 30–36 sessions over 6–9 weeks. Progress is assessed at regular intervals using validated rating scales.

TMS and ketamine therapy address TRD through different mechanisms and have different clinical profiles. They are not mutually exclusive:

Some TRD patients benefit from sequential or combined use — using ketamine's rapid neuroplasticity effect to produce initial response, then consolidating gains with TMS. This is an area of active clinical investigation.

Is TMS painful? Not painful in the typical sense. The tapping sensation is usually well-tolerated after the first session or two. A minority of patients experience headaches during early treatments, which typically resolve.

How quickly will I notice results? Most patients who respond begin noticing improvement around weeks 3–4, with continued improvement through the end of the treatment course.

Will insurance cover TMS? Many major insurers cover TMS for MDD and TRD, typically requiring documentation of prior antidepressant failures. Our practice team helps patients navigate the prior authorization process.

What if TMS doesn't work? Non-response to TMS does not eliminate other options. Ketamine therapy, ECT, further pharmacological augmentation, and functional medicine evaluation remain viable next steps.

How do I access TMS therapy near Pocatello? Contact Roth Family Medicine and Mental Health for a TRD evaluation. We can assess your candidacy, coordinate TMS referral, and manage the full spectrum of your TRD care plan.

1. George MS, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. Arch Gen Psychiatry. 2010;67(5):507–516.
2. Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D). Lancet. 2018;391(10131):1683–1692.
3. Cole EJ, et al. Stanford neuromodulation therapy (SNT): A double-blind randomized controlled trial. Am J Psychiatry. 2022;179(2):132–141.
4. Carpenter LL, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study. Depress Anxiety. 2012;29(7):587–596.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider to determine whether TMS is appropriate for your situation.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | (208)-904-4705 | www.rothfamilymed.com